ArticleRadiation oncology (London, England)2023
Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer.
Article in Radiation oncology (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Development of CBCT-Guided Online Adaptive Radiotherapy.Cancers · 2026Review
- Interfractional shifts of the carina and hilum during radiotherapy for non-small cell lung cancer: A retrospective study to identify associated factors.Journal of applied clinical medical physics · 2025Article
- Time series analysis of dosimetric changes in target volumes and organs at risk monitored by cone beam computed tomography during radiotherapy for non-small-cell lung cancer.Physics and imaging in radiation oncology · 2025Article
- Experience and uncertainty analysis of CT-based adaptive radiotherapy for abdominal treatments.Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2025Article
- Calls to action on lung cancer management and research.The oncologist · 2024Article
- Development of brain metastases in patients managed with non-curative thoracic radiotherapy for stage II/III non-small cell lung cancer.Discover oncology · 2024Article
- Split-Course Adaptive Radioimmunotherapy for Oligometastatic Non-Small Cell Lung Cancer (SiCARIO): A Case Report.Cureus · 2024Article
- Are offline ART decisions for NSCLC impacted by the type of dose calculation algorithm?Technical innovations & patient support in radiation oncology · 2024Article
- Accuracy and Feasibility of Synthetic CT for Lung Adaptive Radiotherapy: A Phantom Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDaily adaptive radiation therapy (ART) of patients with non-small cell lung cancer (NSCLC) lowers organs at risk exposure while maintaining the planning target volume (PTV) coverage. Thus, ART allows an isotoxic approach with increased doses to the PTV that could improve local tumor control. Herein we evaluate daily online ART strategies regarding their impact on relevant dose-volume metrics.
methodsDaily cone-beam CTs (1 × n = 28, 1 × n = 29, 11 × n = 30) of 13 stage III NSCLC patients were converted into synthetic CTs (sCTs). Treatment plans (TPs) were created retrospectively on the first-fraction sCTs (sCT
resultsCompared to the original TPs predicted dose, the median D
conclusionsWe demonstrated that even without reducing safety margins, ART can reduce lung-doses, while still reaching adequate target coverage or escalate target doses without increasing ipsilateral lung exposure. Clinical benefits by means of toxicity and local control of both strategies should be evaluated in prospective clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.